Form D · Biotechnology
RELEVARE PHARMACEUTICALS INC
Brisbane Queenland, C3 · CIK 0001455487
Offering snapshot reported Jun 15, 2012 · SEC filing
- Reported sold
- $750K Offering amount: $750K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 15, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 15, 2012 | Initial | $750,000 | No comparison | 1 | SEC filing |
| Mar 2, 2011 | Initial | $0 | No comparison | 0 | SEC filing |
| Apr 20, 2010 | Initial | $3,040,682 | No comparison | 3 | SEC filing |
| Apr 20, 2010 | Initial | $5,345,405 | No comparison | 4 | SEC filing |
| Feb 2, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-179831
OFFERING IN AUSTRALIAN DOLLARS AND ASSUMING PARITY ON RATE OF FOREIGN EXCHANGE
Source: Form D, filed Jun 15, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Blumling | Director, Executive |
| Andy Gearing | Director |
| Ross Macdonald | Director |
| Andrew Harpur Michell | Director |
| Matthew Morgan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Level 5 Central Plaza 2 66 Eagle Street
Brisbane Queenland, C3, 4001
Brisbane Queenland, C3, 4001